{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:50:04Z","timestamp":1791532204612,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118508","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:41:45Z","timestamp":1790782905000},"page":"118508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Pharmacological translation of cancer missense mutations for therapeutic targeting with small molecules"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0000-133X","authenticated-orcid":false,"given":"Mariam","family":"Fouad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bcp.2026.118508_b0005","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.cell.2022.04.014","article-title":"Systematic discovery of mutation-directed neo-protein-protein interactions in cancer","volume":"185","author":"Mo","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118508_b0010","first-page":"189","article-title":"Decoding the functional impact of the cancer genome through protein-protein interactions","volume":"25","author":"Fu","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.118508_b0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.tig.2020.10.003","article-title":"Hotspots of human mutation","volume":"37","author":"Nesta","year":"2021","journal-title":"Trends Genet."},{"issue":"6","key":"10.1016\/j.bcp.2026.118508_b0020","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1002\/mco2.582","article-title":"Oncogenes and tumor suppressor genes: functions and roles in cancers","volume":"5","author":"Dakal","year":"2024","journal-title":"MedComm"},{"issue":"7","key":"10.1016\/j.bcp.2026.118508_b0025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/cancers17071082","article-title":"Exploring the genetic orchestra of cancer: the interplay between oncogenes and tumor-suppressor genes","volume":"17","author":"Singh","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-23-1510","article-title":"Cell states in cancer: drivers, passengers, and trailers","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118508_b0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.sbi.2021.11.012","article-title":"Implications of disease-related mutations at protein-protein interfaces","volume":"72","author":"Xiong","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0040","doi-asserted-by":"crossref","first-page":"e4861","DOI":"10.1002\/pro.4861","article-title":"Assessing computational tools for predicting protein stability changes upon missense mutations using a new dataset","volume":"33","author":"Zheng","year":"2024","journal-title":"Protein Sci."},{"issue":"W1","key":"10.1016\/j.bcp.2026.118508_b0045","doi-asserted-by":"crossref","first-page":"W338","DOI":"10.1093\/nar\/gkz383","article-title":"mCSM-PPI2: predicting the effects of mutations on protein-protein interactions","volume":"47","author":"Rodrigues","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.118508_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006615","article-title":"PremPDI estimates and interprets the effects of missense mutations on protein-DNA interactions","volume":"14","author":"Zhang","year":"2018","journal-title":"PLoS Comput. Biol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118508_b0055","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.3390\/ijms21155560","article-title":"PremPRI: predicting the effects of missense mutations on protein-RNA interactions","volume":"21","author":"Zhang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0060","doi-asserted-by":"crossref","first-page":"e4527","DOI":"10.1002\/pro.4527","article-title":"RosettaDDGPrediction for high-throughput mutational scans: from stability to binding","volume":"32","author":"Sora","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2026.118508_b0065","article-title":"Systematic evaluation of computational tools to predict the effects of mutations on protein stability in the absence of experimental structures","volume":"23(2):bbac025","author":"Pan","year":"2022","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.bcp.2026.118508_b0070","article-title":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","volume":"381(6664):eadg7492","author":"Cheng","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118508_b0075","article-title":"AlphaMissense for identifying pathogenic missense mutations in DNA damage repair genes in cancer","volume":"9","author":"Yazaki","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bcp.2026.118508_b0080","unstructured":"Gao H, Hamp T, Ede J, Schraiber JG, McRae J, Singer-Berk M, et al. The landscape of tolerated genetic variation in humans and primates. Science. 2023 Jun 2;380(6648):eabn8153. doi: 10.1126\/science.abn8197. Epub 2023 Jun 2. PMID: 37262156; PMCID: PMC10713091."},{"issue":"D1","key":"10.1016\/j.bcp.2026.118508_b0085","doi-asserted-by":"crossref","first-page":"D1143","DOI":"10.1093\/nar\/gkad989","article-title":"CADD v1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions","volume":"52","author":"Schubach","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0090","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1021\/acs.biomac.4c01124","article-title":"Accelerated missense mutation identification in intrinsically disordered proteins using deep learning","volume":"26","author":"Seth","year":"2025","journal-title":"Biomacromolecules"},{"issue":"7","key":"10.1016\/j.bcp.2026.118508_b0095","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ajhg.2025.04.017","article-title":"Prioritizing disease-associated missense variants with chemoproteomic-detected amino acids","volume":"112","author":"Palafox","year":"2025","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.bcp.2026.118508_b0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1101\/gr.176601","article-title":"Predicting deleterious amino acid substitutions","volume":"11","author":"Ng","year":"2001","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat. Methods"},{"issue":"18","key":"10.1016\/j.bcp.2026.118508_b0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418100122","article-title":"Accurate identification and mechanistic evaluation of pathogenic missense variants with Rhapsody-2","volume":"122","author":"Banerjee","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.bcp.2026.118508_b0115","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1093\/bioinformatics\/btz184","article-title":"FoldX 5.0: working with RNA, small molecules and a new graphical interface","volume":"35","author":"Delgado","year":"2019","journal-title":"Bioinformatics"},{"issue":"W1","key":"10.1016\/j.bcp.2026.118508_b0120","doi-asserted-by":"crossref","first-page":"W350","DOI":"10.1093\/nar\/gky300","article-title":"DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability","volume":"46","author":"Rodrigues","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","article-title":"REVEL: an ensemble method for predicting the pathogenicity of rare missense variants","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2026.118508_b0130","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1038\/s41467-020-19669-x","article-title":"Inferring the molecular and phenotypic impact of amino acid variants with MutPred2","volume":"11","author":"Pejaver","year":"2020","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2026.118508_b0135","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/healthcare11121808","article-title":"Ensemble learning for disease prediction: a review","volume":"11","author":"Mahajan","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"11","key":"10.1016\/j.bcp.2026.118508_b0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nmeth.2642","article-title":"IntOGen-mutations identifies cancer drivers across tumor types","volume":"10","author":"Gonzalez-Perez","year":"2013","journal-title":"Nat. Methods"},{"issue":"13","key":"10.1016\/j.bcp.2026.118508_b0145","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1158\/0008-5472.CAN-15-3190","article-title":"Exome-scale discovery of hotspot mutation regions in human cancer using 3D protein structure","volume":"76","author":"Tokheim","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118508_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077945","article-title":"CanDrA: cancer-specific driver missense mutation annotation with optimized features","volume":"8","author":"Mao","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2026.118508_b0155","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molmed.2023.03.007","article-title":"Cancer driver mutations: predictions and reality","volume":"29","author":"Ostroverkhova","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcp.2026.118508_b0160","doi-asserted-by":"crossref","unstructured":"Landrum MJ, Chitipiralla S, Kaur K, Brown G, Chen C, Hart J, et al. ClinVar: updates to support classifications of both germline and somatic variants. Nucleic Acids Res. 2024:gkae1090. doi: 10.1093\/nar\/gkae1090.","DOI":"10.1093\/nar\/gkae1090"},{"issue":"D1","key":"10.1016\/j.bcp.2026.118508_b0165","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118508_b0170","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/humu.21517","article-title":"dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions","volume":"32","author":"Liu","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bcp.2026.118508_b0175","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/humu.24309","article-title":"Variant interpretation using population databases: lessons from gnomAD","volume":"43","author":"Gudmundsson","year":"2022","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bcp.2026.118508_b0180","article-title":"Missense mutations in cancer: in silico predictions, developing treatments, and overcoming cell resistance","author":"Fouad","year":"2025","journal-title":"ChemRxiv"},{"issue":"7","key":"10.1016\/j.bcp.2026.118508_b0185","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118508_b0190","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tips.2022.03.011","article-title":"Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer","volume":"43","author":"Ganguly","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118508_b0195","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.orglett.2c04266","article-title":"Synthesis of adagrasib (MRTX849), a covalent KRASG12C inhibitor drug for the treatment of cancer","volume":"25","author":"Chen","year":"2023","journal-title":"Org. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2026.118508_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00341-0","article-title":"BRAF V600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study","volume":"7","author":"Nelson","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118508_b0210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3-mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2026.118508_b0215","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bcp.2026.118508_b0220","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/acsptsci.2c00164","article-title":"Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C","volume":"5","author":"Stephenson Clarke","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","article-title":"Discovery of rezatapopt (PC14586), a first-in-class, small-molecule reactivator of p53 Y220C mutant in development","volume":"16","author":"Vu","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118508_b0230","article-title":"Rescuing the function of missense-mutated tumor suppressor VHL using stabilizing small molecules","volume":"15","author":"Fouad","year":"2026","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0235","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2026.118508_b0240","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.118508_b0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118508_b0255","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118508_b0260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-023-44376-8","article-title":"Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA","volume":"15","author":"Teuber","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2026.118508_b0265","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118508_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1133472","article-title":"Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights","volume":"11","author":"Ragupathi","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0275","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13072-025-00590-w","article-title":"Chromatin remodeling and cancer: the critical influence of the SWI\/SNF complex","volume":"18","author":"Hao","year":"2025","journal-title":"Epigenetics Chromatin"},{"issue":"3","key":"10.1016\/j.bcp.2026.118508_b0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/13543776.2024.2338111","article-title":"Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023","volume":"34","author":"Reichl","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/0008-5472.CAN-25-1141","article-title":"PRT3789 is a first-in-human SMARCA2-selective degrader that induces synthetic lethality in SMARCA4-mutated cancers","volume":"86","author":"Hulse","year":"2026","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0290","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1038\/s41467-025-64669-4","article-title":"Rational design of potent small-molecule SMARCA2\/A4 degraders acting via the recruitment of FBXO22","volume":"16","author":"Villemure","year":"2025","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.bcp.2026.118508_b0295","first-page":"00198","article-title":"Mechanistic dissection of SMARCA2\/4 molecular glues reveals programmable switching between DCAF16 and FBXO22","volume":"S2451\u20139456","author":"Rouhimoghadam","year":"2026","journal-title":"Cell Chem. Biol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118508_b0300","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bcp.2026.118508_b0305","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2026.118508_b0310","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118508_b0315","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdw129","article-title":"Osimertinib (AZD9291) \u2014 a science-driven, collaborative approach to rapid drug design and development","volume":"27","author":"Yver","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0320","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"issue":"1482","key":"10.1016\/j.bcp.2026.118508_b0325","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1098\/rstb.2007.2026","article-title":"Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy","volume":"362","author":"Zhou","year":"2007","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118508_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104783","article-title":"Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review of safety and efficacy","volume":"213","author":"Dali","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118508_b0335","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-targeting PROTACs","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2026.118508_b0340","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bcp.2026.118508_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteasome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0350","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"16","key":"10.1016\/j.bcp.2026.118508_b0355","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118508_b0360","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of elironrasib (RMC-6291), a potent and orally bioavailable, RAS(ON) G12C-selective, covalent tricomplex inhibitor for the treatment of patients with RAS G12C-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118508_b0365","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118508_b0370","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nchembio.2171","article-title":"Overcoming resistance to HER2 inhibitors through state-specific kinase binding","volume":"12","author":"Novotny","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118508_b0375","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1158\/2767-9764.CRC-23-0302","article-title":"HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer","volume":"3","author":"Olson","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0380","doi-asserted-by":"crossref","first-page":"873","DOI":"10.20517\/cdr.2022.48","article-title":"Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer","volume":"5","author":"Eli","year":"2022","journal-title":"Cancer Drug Resist."},{"issue":"11","key":"10.1016\/j.bcp.2026.118508_b0385","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/17512433.2017.1387051","article-title":"Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis","volume":"10","author":"Kayser","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118508_b0390","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \u201cgatekeeper\u201d F691L mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2026.118508_b0395","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bmc.2011.12.021","article-title":"Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)","volume":"20","author":"Kinoshita","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118508_b0400","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/jm401805h","article-title":"Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib","volume":"57","author":"Huang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bcp.2026.118508_b0405","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood-2009-11-251751","article-title":"Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants","volume":"115","author":"Weisberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118508_b0410","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat Cancer."},{"issue":"16 suppl","key":"10.1016\/j.bcp.2026.118508_b0415","article-title":"NTRK1-3 point mutations in non-small cell lung cancer: molecular profiling","volume":"43","author":"Park","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:12:36Z","timestamp":1791529956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":83,"alternative-id":["S0006295226008506"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118508","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological translation of cancer missense mutations for therapeutic targeting with small molecules","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118508"}}